Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet

Journal article

McClung, M. R., Miller, P. D., Brown, J. P., Zanchetta, J., Bolognese, M. A., Benhamou, C. L., Balske, A., Burgio, D. E., Sarley, J., McCullough, L. K. and Recker, R. R.. (2012). Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Osteoporosis International. 23(1), pp. 267 - 276. https://doi.org/10.1007/s00198-011-1791-y
AuthorsMcClung, M. R., Miller, P. D., Brown, J. P., Zanchetta, J., Bolognese, M. A., Benhamou, C. L., Balske, A., Burgio, D. E., Sarley, J., McCullough, L. K. and Recker, R. R.
Abstract

Dosing regimens of oral bisphosphonates are inconvenient and contribute to poor compliance. The bone mineral density response to a once weekly delayed-release formulation of risedronate given before or following breakfast was non-inferior to traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient regimen for oral bisphosphonate therapy.

Keywordsbone mineral density; delayed-release; enteric-coated; fracture risk; osteoporosis; risedronate; weekly
Year2012
JournalOsteoporosis International
Journal citation23 (1), pp. 267 - 276
PublisherSpringer-Verlag
ISSN0937-941X
Digital Object Identifier (DOI)https://doi.org/10.1007/s00198-011-1791-y
Scopus EID2-s2.0-84857360001
Page range267 - 276
Research GroupInstitute for Health and Ageing
Publisher's version
File Access Level
Controlled
Place of publicationUnited Kingdom
Permalink -

https://acuresearchbank.acu.edu.au/item/873zv/efficacy-and-safety-of-a-novel-delayed-release-risedronate-35-mg-once-a-week-tablet

Log in to edit

Restricted files

Publisher's version

  • 43
    total views
  • 0
    total downloads
  • 1
    views this month
  • 0
    downloads this month
These values are for the period from 19th October 2020, when this repository was created.

Export as